NICE Favors Zolgensma Being Added to England’s Public Health Program

NICE Favors Zolgensma Being Added to England’s Public Health Program

England’s National Institute for Health and Care Excellence (NICE) issued its final Zolgensma’s appraisal, recommending that the gene therapy be covered by the country’s national health service (NHS) and provided at low or no cost to eligible spinal muscular...

read more
NICE Initially Against Adding Evrysdi to UK Public Health System

NICE Initially Against Adding Evrysdi to UK Public Health System

The initial position of England’s National Institute for Health and Care Excellence (NICE) is to recommend against adding Roche’s Evrysdi (risdiplam) to the list of medications available to spinal muscular atrophy (SMA) patients through the country’s national health...

read more